A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Previously Treated With Bonviva
NCT ID: NCT00081653
Last Updated: 2017-07-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
719 participants
INTERVENTIONAL
2004-05-31
2008-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis
NCT00048061
A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
NCT00129623
A Study of Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis Who Have Received Previous Bonviva Treatment
NCT00551174
A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.
NCT00377234
A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia
NCT02604836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
ibandronate [Bonviva/Boniva]
150mg po monthly for 3 years
2
ibandronate [Bonviva/Boniva]
100mg po monthly for 3 years
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ibandronate [Bonviva/Boniva]
150mg po monthly for 3 years
ibandronate [Bonviva/Boniva]
100mg po monthly for 3 years
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ambulatory.
Exclusion Criteria
* breast cancer diagnosed within the previous 22 years.
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Loma Linda, California, United States
Lakewood, Colorado, United States
Omaha, Nebraska, United States
Livingston, New Jersey, United States
Portland, Oregon, United States
Liège, , Belgium
Merksem, , Belgium
São Paulo, , Brazil
Pilsen, , Czechia
Prague, , Czechia
Aalborg, , Denmark
Ballerup Municipality, , Denmark
Vejle, , Denmark
Lyon, , France
Berlin, , Germany
Hanover, , Germany
Balatonfüred, , Hungary
Budapest, , Hungary
Budapest, , Hungary
Kiskunhalas, , Hungary
Zalaegerszeg, , Hungary
Siena, , Italy
León, , Mexico
Obregón, , Mexico
Haugesund, , Norway
Stavanger, , Norway
Krakow, , Poland
Warsaw, , Poland
Barcelona, , Spain
Madrid, , Spain
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MA17903
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.